The enrichment of MDS-linked mutations (TP53, RUNX1, ASXL1, and U2AF1), clinical annotations of prior MDS status and the MDS-like gene expression signature indicate that MDS-like AML cases have a unique molecular phenotype associated with poor survival. Here, TP53 is linked to myelodysplastic syndrome.